Real-World Evaluation of Clinical Response and Long-Term Healthcare Resource Utilization Patterns Following Treatment with a Digital Therapeutic for Chronic Insomnia
Felicia Forma,Tyler G Knight,Frances P Thorndike,Xiaorui Xiong,Rebecca Baik,Fulton F Velez,Yuri A Maricich,Daniel C Malone
DOI: https://doi.org/10.2147/CEOR.S368780
2022-08-11
ClinicoEconomics and Outcomes Research
Abstract:Felicia Forma, 1 Tyler G Knight, 2 Frances P Thorndike, 1 Xiaorui Xiong, 1 Rebecca Baik, 2 Fulton F Velez, 1 Yuri A Maricich, 1 Daniel C Malone 3 1 Pear Therapeutics, Inc., Medical Affairs Department, Boston, MA, USA; 2 Labcorp Drug Development, Market Access Consulting Department, Gaithersburg, MD, USA; 3 Strategic Therapeutics, LLC, Oro Valley, AZ, USA Correspondence: Felicia Forma, Pear Therapeutics, Medical Affairs Department, 200 State St, Boston, MA, 02109, USA, Email Background and Objectives: This analysis evaluated insomnia severity and long-term impact on healthcare resource utilization (HCRU) and costs after treatment with Somryst ® (previously called SHUTi), a digital therapeutic delivering cognitive behavioral therapy for insomnia (CBT-I). Methods: Change from baseline in insomnia severity index (ISI) score was assessed using last observed ISI score. A pre/post analysis of claims data was conducted, comparing HCRU in patients with self-identified sleep problems who successfully initiated the therapeutic (index date) between June 1, 2016 and December 31, 2018. Results: A total of 248 patients were analyzed (median age 56.5 years, 57.3% female, mean ISI score 19.13, 52.4% treated with sleep aid medications pre-index). After 9 weeks, mean ISI score declined by 37.2% from baseline (19.1 vs 12.0), 58.8% of patients achieved ISI responder status (ISI score improved by => 7; NNT: 1.7), and 26.6% of patients achieved insomnia remission (ISI score < 8; NNT for remission: 3.8). After two-year follow-up, post-index events were reduced (compared to 2 years pre-index) for emergency department visits (− 53%; IRR: 0.47; 95% CI 0.27, 0.82; P =0.008), hospiatizations (-21%; IRR: 0.79; 95% CI 0.46, 1.35; P =0.389) and hospital outpatient visits (− 13%; IRR: 0.87; 95% CI 0.66, 1.14; P =0.315). Slightly increased rates were observed for ambulatory surgical center visits (2%; IRR: 1.02; 95% CI 0.73, 1.44; P =0.903) and office visits (2%; IRR: 1.02; 95% CI 0.92, 1.14; P =0.672). The number of patients treated with sleep aid medications dropped 18.5% (52.4% pre-index vs 42.7% post-index). Average number of prescriptions decreased from 3.98 pre-index to 3.73 post-index ( P = 0.552). Total two-year cost reduction post-index vs pre-index was 2059 per patient. Conclusion: In a real-world cohort of patients with chronic insomnia, treatment with a digital therapeutic delivering CBT-I was associated with reductions in insomnia severity, emergency department visits, and net costs. Keywords: CBT-I, cognitive behavioral therapy for insomnia, chronic insomnia, prescription digital therapeutic, SHUTi, Somryst Many people have insomnia, which is difficulty falling asleep or staying asleep. The recommended treatment for insomnia is a type of therapy called cognitive behavioral therapy for insomnia, or CBT-I. CBT-I is very effective, but few people actually use it. Prescription digital therapeutics (PDTs) are FDA-authorized treatments that people use on mobile devices. This study looked at whether the use of a PDT for insomnia by 248 adults led to reduced symptoms at the end of treatment, and whether use of the PDT led to lower health care costs two years after treatment. At the end of treatment, average scores on a measure of insomnia symptoms declined by 37.2% compared to the start of the study, and 26.6% of the group reported that their insomnia was no longer a problem. Compared to the two years before treatment with the PDT, emergency department visits were 53% lower two years after treatment, hospitalizations were 21% lower, and hospital outpatient visits were 13% lower. The number of patients treated with sleep aid medications dropped 18.5%. The reduced use of health care facilities led to a savings, after two years, of $2059 per patient treated with the PDT. The reductions in insomnia symptoms and long-term health care costs observed in this study suggest that use of a PDT for insomnia is both clinically and economically effective, which may lead to wider use of this non-drug form of insomnia treatment. Insomnia is defined as trouble initiating or maintaining sleep with daytime symptoms of impaired decision making, work performance, and quality of life. 1 About one-third of adults in the United States (US) report that they have difficulty with sleep initiation or sleep maintenance at least weekly 2,3 and it is estimated that between 6% and 15% meet the criteria of insomnia (sleep disturbance and significant daytime dysfunction). 2,4 The COVID-19 pandemic has exacerbated insomnia, due to disrupted circadian rhythms, 5-Abstract Truncated-